Skip to content

JBIO JBIO Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$608K

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: JBIO’s 10-Q, filed August 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about JBIO's capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's capital investments accrued but not yet paid?
JBIO (JBIO) reported capital investments accrued but not yet paid of $11K in Q2 2025.